Last deal

$5.2M

Amount

Grant

Stage

02.07.2024

Date

3

all rounds

$180.5M

Total amount

date founded

Financing round

General

About Company
Mission Therapeutics is a drug discovery company targeting deubiquitylating enzymes.

Industry

Sector :

Subsector :

Keywords :

Also Known As

ImmVaRx

founded date

01.01.2011

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

Mission Therapeutics develops small molecule drugs that selectively target deubiquitylating enzymes (DUBs) to treat serious diseases. With a world-leading platform, the company is focused on advancing its pipeline programs through early clinical development, prioritizing patient selection strategies to demonstrate early signs of efficacy. Mission Therapeutics has strong partnerships with academic and research centers, and has received significant venture capital funding. Based in Cambridge, UK, the company is a leader in the field of deubiquitylating enzymes and is currently developing DUB inhibitors for various disease indications including kidney disease, mitochondrial diseases, neurodegenerative diseases, and fibrosis.
Contacts

Contact Email

Phone number

Social url

Legal Names

Legal name

Mission Therapeutics Ltd.
Similar Companies
1000
Cend Therapeutics Inc.

Cend Therapeutics Inc.

Cend Therapeutics Inc. develops cancer therapies that overcome drug delivery barriers to solid tumors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

La Jolla, San Diego, CA, USA

total rounds

2

total raised

$3.1M
Belharra Therapeutics

Belharra Therapeutics

Belharra Therapeutics is a drug discovery company specializing in transformative medicines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Diego, CA, USA

total rounds

1

total raised

$50M
Sareum Holdings PLC

Sareum Holdings PLC

Sareum develops targeted therapeutics for cancer and autoimmune diseases, aiming to license them to pharmaceutical companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Pampisford, Cambridge CB22, UK

total rounds

2

total raised

$3.81M
NovelMed Therapeutics

NovelMed Therapeutics

NovelMed Therapeutics develops transformative treatments for orphan and non-orphan diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Biopharma, Health Care

Location

Cleveland, OH, USA

total rounds

1

total raised

$1.43M

Financials

Funding Rounds
9
3

Number of Funding Rounds

$180.5M

Money Raised

Their latest funding was raised on 02.07.2024. Their latest investor Michael J. Fox Foundation. Their latest round Grant

Date 
Funding Round 
Investors 
Money Raised 
Lead 
14.03.2024
6
$32.22M
Local Amount - GBP 25.2M
Michael J. Fox Foundation

Michael J. Fox Foundation

Michael J. Fox Foundation is a non-profit research firm dedicated to finding better treatments and a cure for Parkinson's disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Financial Services, Non-Profit

Location

New York, NY, USA

count Of Investments

71

count Of Exists

5
IP Group

IP Group

IP Group creates value for shareholders and partners by commercialising intellectual property from research institutions.

Sector

General Industrials

Subsector

Diversified Industrials

Location

London, UK

total rounds

1

total raised

$30M

count Of Investments

248

count Of Exists

15
Sofinnova Partners

Sofinnova Partners

Sofinnova Partners is a venture capital firm that invests in life sciences.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Paris, France

total rounds

1

count Of Investments

284

count Of Exists

40
Rosetta Capital

Rosetta Capital

Rosetta Capital Limited is a London-based private equity and venture capital firm focused on direct secondary investments.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Finance

Location

London, UK

count Of Investments

13
Pfizer Venture Investments

Pfizer Venture Investments

Pfizer Venture Investments is a VC firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

Location

New York, NY, USA

count Of Investments

136

count Of Exists

21
Michael J. Fox Foundation

Michael J. Fox Foundation

Michael J. Fox Foundation is a non-profit research firm dedicated to finding better treatments and a cure for Parkinson's disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Financial Services, Non-Profit

Location

New York, NY, USA

count Of Investments

71

count Of Exists

5
Co-Investors
Investors
10
7

Number of lead investors

10

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Venture - Series Unknown
No
Venture - Series Unknown
Michael J. Fox Foundation

Michael J. Fox Foundation

Michael J. Fox Foundation is a non-profit research firm dedicated to finding better treatments and a cure for Parkinson's disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Financial Services, Non-Profit

Location

New York, NY, USA

count Of Investments

71

count Of Exists

5
IP Group

IP Group

IP Group creates value for shareholders and partners by commercialising intellectual property from research institutions.

Sector

General Industrials

Subsector

Diversified Industrials

Location

London, UK

total rounds

1

total raised

$30M

count Of Investments

248

count Of Exists

15
Roche Venture Fund

Roche Venture Fund

Roche Venture Fund invests in and developing innovative life science companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Basel, Switzerland

count Of Investments

83

count Of Exists

19

People

Founders
3
Xavier Jacq
Xavier Jacq

Xavier Jacq

XavierXavier Jacq obtained his PhD from Louis Pasteur University in Strasbourg, France in 1997. He then carried out post-doctoral training at Columbia University, NY, USA in cancer biology. Following a first industry experience at Sanofi-Synthelabo, Xavier joined Hybrigenics in Paris as a project leader in 2002 where he became interested in targeting the ubiquitin proteasome pathway in the oncology field. He is an inventor on multiple patents related to inhibitors of deubiquitylating enzymes and assays.

organization founded

1

Xavier Jacq

Steve Jackson
Steve Jackson

Steve Jackson

After graduating in biochemistry from the University of Leeds followed by a PhD from Edinburgh University, Steve carried out post-doctoral training in the lab of Professor Robert Tjian at Berkeley, USA. In 1991, he became a group leader at what is now the Gurdon Institute in Cambridge, UK, where he is now Senior Group Leader and Head of Cancer Research UK Laboratories. Steve is also the University of Cambridge’s Frederick James Quick Chair of Biology. His research has been instrumental in shaping our understanding of cellular responses to DNA damage and of how defects in these responses contribute to disease. Steve co-founded KuDOS Pharma which was acquired by AstraZeneca in 2006. Olaparib, which was originated by KuDOS, was approved for advanced BRCA+ ovarian cancer in USA and Europe in 2014.

current job

MISSION Therapeutics
MISSION Therapeutics

organization founded

1

Steve Jackson

Niall Martin
Niall Martin

Niall Martin

Niall Martin is the Chief Executive Officer at Artios Pharma.

current job

Artios Pharma
Artios Pharma

organization founded

1

Niall Martin

Employee Profiles
11
Jonathan Hepple

Jonathan Hepple

Non Executive Director

Colin Goddard

Board member

Deborah Harland

Deborah Harland

Non Executive Director

Steve Jackson

Steve Jackson

Co-Founder & CSO

Paul Thompson

Paul Thompson

Chief Scientific Officer

Graziano Seghezzi

Graziano Seghezzi

Team Member

Anker Lundemose

Anker Lundemose

CEO

Michael Koslowski

Executive Vice President, Research and Development and Chief Medical Officer

Activity

Recent News
2
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month